Kala Bio (KALA) Operating Margin (2019 - 2022)
Kala Bio (KALA) posted Operating Margin of 3468.81% for Q3 2022, down 180.48% sequentially from 1236.76% in Q2 2022, and down 261876.0% YoY from N/an in Q3 2021.
Kala Bio (KALA) Operating Margin (2019 - 2022) Analysis & Trends
Kala Bio has reported Operating Margin for 4 years, with the latest figure at 3468.81% in Q3 2022.
- Quarterly Operating Margin fell 261876.0% year-over-year to 3468.81% in Q3 2022, while the trailing twelve-month figure through Dec 2022 was 2099.33% (down 94057.0% YoY) and the FY2022 annual result came in at 2099.33%, down 94057.0% from the prior year.
- Operating Margin retreated to 3468.81% in Q3 2022 per KALA's latest filing, from 1236.76% in the prior quarter.
- Over five years, Operating Margin peaked at 850.05% in Q3 2021 and troughed at 3468.81% in Q3 2022.
- A 4-year average of 1671.04% and a median of 1486.35% in 2019 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2021 and 2022: Operating Margin jumped 160264 bps in 2021, then plunged 261876 bps in 2022.
- Over 4 years, Operating Margin stood at 1711.61% in 2019, then rose by 24 bps to 1295.08% in 2020, then sank by 95 bps to 2522.36% in 2021, then sank by 38 bps to 3468.81% in 2022.
- According to Business Quant data, Operating Margin over the past three periods registered 3468.81%, 1236.76%, and 2253.21% for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -3,468.81% |
| Jun 30, 2022 | -1,236.76% |
| Mar 31, 2022 | -2,253.21% |
| Dec 31, 2021 | -2,522.36% |
| Sep 30, 2021 | -850.05% |
| Jun 30, 2021 | -951.98% |
| Mar 31, 2021 | -866.93% |
| Dec 31, 2020 | -1,295.08% |
| Sep 30, 2020 | -1,164.05% |
| Jun 30, 2020 | -2,554.62% |
| Mar 31, 2020 | -1,879.08% |
| Dec 31, 2019 | -1,711.61% |
| Sep 30, 2019 | -1,486.35% |
| Jun 30, 2019 | -1,089.45% |
| Mar 31, 2019 | -1,735.21% |